End points | Dabigatran 110 mg ×2 | Dabigatran 150 mg ×2 | Warfarin | NNT/NNH: dabigatran 110 mg | NNT/NNH: dabigatran 150 mg |
---|---|---|---|---|---|
Primary outcomes (%) | 1.53 | 1.11 | 1.69 | 625 | 172 |
Myocardial infarction (%) | 0.7 | 0.7 | 0.5 | 500 | 500 |
Mortality (%) | 3.8 | 3.6 | 4.1 | 330 | 200 |
Major bleeding (%) | 2.7 | 3.1 | 3.4 | 143 | 333 |
Intracranial bleeding (%) | 0.2 | 0.3 | 0.7 | 200 | 250 |
Net clinical benefits (%) | 7.1 | 6.9 | 7.6 | 200 | 143 |